

ETL Opening Ceremony

April 17, 2012

Evonik Industries held today its opening ceremony for Evonik Tianda (Liaoyang) Chemical Additive Co., Ltd. (ETL) in Liaoyang National Aromatic and Fine Chemical High-Tech Industrialization Zone (LAS). ETL, a joint venture between Evonik China and Tianda Electrical Company, moved to the North China multi-user-site (Northern MUSC) of Evonik in September 2010.

“Our investment in Liaoyang is a key aspect of our global growth strategy,” said Evonik Executive Board member Dr. Dahai Yu. “As a leading supplier of specialty chemicals, we focus on fast-growing megatrends such as health, nutrition, resource efficiency and globalization as well as appealing markets of tomorrow.”

ETL produces triacetoneamine derivatives (TAA derivatives), which are recognized as essential building blocks for the production of Hindered Amine Light Stabilizer (H.A.L.S.). These additives are used in low concentrations to protect and stabilize polymers against decomposition by light, oxygen and heat. The main applications are in the automotive and construction industries as well as agricultural films.

“We are targeting Asia's fast-growing markets,” explained Jan Van den Bergh, head of the Advanced Intermediates Business Unit. “We are focusing on China in particular. Our commitment to Liaoyang is another aspect of our growth strategy, which helps us to single-mindedly advance our business operations.”

Demand for TAA derivatives has kept rising for several years. The new plant will give the flexibility to cater for the market needs in China and offers reliability of supply.

Evonik is a leading global producer of TAA and its derivatives. It offers a wide range of its derivatives (e.g. Hexamethylene-bis(triacetone) diamine, Triacetone diamine) and also tailor made molecules based on TAA. Apart from the plant in Liaoyang, Evonik has further production capacities at Marl Chemical Park in Germany.

Cathy Ho

Communications
Tel +86 21 6119-1296
Fax +86 21 6119-1116
cathy.ho@evonik.com

Joanne Lu

Communications
Tel +86 21 6119-1000
Fax +86 21 6119-1605
joanne.lu@evonik.com

Evonik Industries AG

Rellinghauser Strasse 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Chairman of the Supervisory Board

Wilhelm Bonse-Geuking
Executive Board
Dr. Klaus Engel, Chairman
Dr. Wolfgang Colberg,
Dr. Thomas Haeberle, Thomas
Wessel,
Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen
Register Court: Essen Local Court
Commercial Registry B 19474
VAT ID no. DE 811160003

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.

Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970's; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavour to grow our business in the region. The company now has around 3,500 employees in the Greater China region, the regional sales reached over 1.2 billion in 2011.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.